BioCentury
ARTICLE | Company News

Takeda grants newco Izana rights to autoimmune candidate

December 15, 2017 9:42 PM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) granted newco Izana Bioscience (London, UK) exclusive, worldwide rights to develop and commercialize namilumab (MT203, IZN-101). Takeda will receive an undisclosed equity stake in the newco. Next half, Izana plans to begin a Phase II trial of namilumab to treat ankylosing spondylitis.

Izana also received a £1.4 million ($1.9 million) grant from Innovate UK to support the trial...